Key facts
- This page summarizes David Arkowitz's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 31 Oct 2023, 21:39.
David Arkowitz - 27 Oct 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- MCRB
- Reported as of
- 27 Oct 2023
- Net transaction value
- -$5,489
- SEC form
- 4
- Accepted by SEC
- 31 Oct 2023, 21:39:11 UTC
- Prior SEC filing
- 01 May 2023
- Next SEC filing
- 16 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Arkowitz filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 31 Oct 2023.
Change
- Previous filing in this sequence was filed on 01 May 2023.
- Current net transaction value: -$5,489.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MCRB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +13,209
- Change %
- +7.9%
- Price
- $0.000000
- Shares after
- 179,822
- Date
- 27 Oct 2023
- Ownership
- Direct
- Footnotes
- F1
MCRB
transaction
Common Stock
Sale
- Transaction value
- $5,489
- Shares
- -4,066
- Change %
- -2.3%
- Price
- $1.35
- Shares after
- 175,756
- Date
- 30 Oct 2023
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MCRB
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +26,418
- Change %
- Price
- $0.000000
- Shares after
- 26,418
- Date
- 27 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,418
- Exercise price
- Footnotes
- F1, F4
MCRB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -13,209
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 13,209
- Date
- 27 Oct 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,209
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
On February 3, 2023, the reporting person was granted an award of 26,418 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,209 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,209 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 21, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
Footnote F3
The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.35 to $1.365, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.